Skip to main content

Advertisement

Log in

A time since onset of injection model for hepatitis C spread amongst injecting drug users

  • Published:
Journal of Mathematical Biology Aims and scope Submit manuscript

Abstract

Studies of hepatitis C virus (HCV) infection amongst injecting drug users (IDUs) have suggested that this population can be separated into two risk groups (naive and experienced) with different injecting risk behaviours. Understanding the differences between these two groups and how they interact could lead to a better allocation of prevention measures designed to reduce the burden of HCV in this population. In this paper we develop a deterministic, compartmental mathematical model for the spread of HCV in an IDU population that has been separated into two groups (naive and experienced) by time since onset of injection. We will first describe the model. After deriving the system of governing equations, we will examine the basic reproductive number \(R_0\), the existence and uniqueness of equilibrium solutions and the global stability of the disease free equilibrium (DFE) solution. The model behaviour is determined by the basic reproductive number, with \(R_0=1\) a critical threshold for endemic HCV prevalence. We will show that when \(R_0\le 1\), and HCV is initially present in the population, the system will tend towards the globally asymptotically stable DFE where HCV has been eliminated from the population. We also show that when \(R_0>1\) there exists a unique non-zero equilibrium solution. Then we estimate the value of \(R_0\) from epidemiological data for Glasgow and verify our theoretical results using simulations with realistic parameter values. The numerical results suggest that if \(R_0>1\) and the disease is initially present then the system will tend to the unique endemic equilibrium.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Advisory Council on the Misuse of Drugs (2009) The primary prevention of Hepatitis C among injecting drug users. http://drugs.homeoffice.gov.uk/publication-search/acmd/acmdhepcreport22835.pdf (accessed 2010)

  • Aitken CK, Lewis J, Tracy SL, Spelman T, Bharadwaj M, Bowden DS, Drummer H, Hellard ME (2008) High incidence of Hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48:1749–1752

    Article  Google Scholar 

  • Cassin S, Geoghegan T, Cox G (1998) Young injectors: a comparative analysis of risk behaviour. Ir J Med Sci 167:234–237

    Article  Google Scholar 

  • Corson S, Greenhalgh D, Hutchinson S (2011) Mathematically modelling the spread of hepatitis C in injecting drug users. Math Med Biol. doi:10.1093/imammb/dqr011

  • Corson S, Greenhalgh D, Palmateer N, Weir A, Hutchinson S (2011) Risk of hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. Int J Drug Policy 22:102–108

    Article  Google Scholar 

  • Diekmann O, Heesterbeek JAP (2000) Mathematical epidemology of infectious diseases: model building, analysis and interpretation. Wiley series in mathematical and computational biology. Wiley, Sussex

    Google Scholar 

  • Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, Purcell RH (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135–140

    Article  Google Scholar 

  • Frischer M, Leyland A, Cormack R, Goldberg DJ, Bloor M, Green ST, Taylor A, Covell R, McKeganey N, Platt S (1993) Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injection drug users in Glasgow, Scotland. Am J Epidemiol 138: 170–181

    Google Scholar 

  • Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D (1998) Prevalence and incidence of Hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr 18:S11–S19

    Google Scholar 

  • Gatica JA, Smith HL (1977) Fixed point techniques in a cone with applications. J Math Anal Appl 61:58–71

    Article  MathSciNet  MATH  Google Scholar 

  • Greenhalgh D (1993) Existence, threshold and stability results for an age-structured epidemic model with vaccination and non separable transmission coefficient. Int J Syst Sci 24:641–668

    Article  MathSciNet  MATH  Google Scholar 

  • Greenhalgh D (1997) Bounds on endemic disease levels, risks and basic reproductive numbers in heterogeneous models for HIV/AIDS amongst injecting drug users. J Biol Syst 5:151–180

    Article  MATH  Google Scholar 

  • Gruer L, Cameron J, Elliot L (1993) Building a city wide service for exchanging needles and syringes. Br Med J 306:1394–1397

    Article  Google Scholar 

  • Hagan H, des Jarlais D (2000) HIV and HCV infection among injecting drug users. Mt Sinai J Med 67: 423–428

    Google Scholar 

  • Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR (2002) Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 186:1558–1564

    Article  Google Scholar 

  • Hope VD, Judd A, Hickman M, Lamagni T, Hunter G, Stimson GV, Jones S, Donovan L, Parry JV, Gill ON (2001) Prevalence of Hepatitis C among injection drug users in England and Wales: is harm reduction working? Am J Public Health 91:38–42

    Article  Google Scholar 

  • HPS (1990–1993) Health protection Scotland survey of Glasgow IDUs during 1990–1993. Health Protection Scotland, Glasgow

  • HPS (2008–2009) Health Protection Scotland survey of Glasgow IDUs in 2008–2009. Health Protection Scotland, Glasgow

  • Hutchinson S, Bird S, Taylor A, Goldberg D (2006) Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int J Drug Policy 17:211–221

    Article  Google Scholar 

  • Hutchinson S, Taylor A, Goldberg D, Gruer L (2000) Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990 to 1994: Implications for control and prevention of blood-borne viruses. Addiction 95:931–940

    Article  Google Scholar 

  • Judd A, Hutchinson S, Wadd S, Hickman M, Taylor A, Jones S, Parry J, Cameron S, Rhodes T, Ahmed S, Bird S, Fox R, Renton A, Stimson G, Goldberg D (2005) Prevalence of, and risk factors for, Hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 12:655–662

    Article  Google Scholar 

  • Kapadia F, Vlahov D, des Jarlais DC, Strathdee SA, Ouellet L, Morse EVE, Williams I, Garfein RS, Second Collaborative Injection Drug User Study (CIDUS-II) Group (2002) Does bleach disinfection of syringes protect against Hepatitis C infection among young adult injection drug users? Epidemiology 13:738–741

    Google Scholar 

  • Kaplan EH, O’Keefe E (1993) Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces 23:7–26

    Article  Google Scholar 

  • Kretzschmar M, Wiessing L (2004) Modelling the transmission of Hepatitis C in injecting drug users. In: Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L (eds) Hepatitis C and injecting drug use: impact, costs and policy options. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, pp 143–159

    Google Scholar 

  • Kreyszig E (1989) Introductory functional analysis with applications. Wiley, USA

    MATH  Google Scholar 

  • Lajmanovich A, Yorke JA (1976) A deterministic model for Gonorrhea in a non-homogeneous population. Math Biosci 28:221–236

    Article  MathSciNet  MATH  Google Scholar 

  • Macey R, Oster G, Zahnley T (2000) Berkeley Madonna, UC Berkeley, USA. http://www.berkeleymadonna.com (accessed 2008)

  • Mathei C, van Dooreen S, Lemey P, van Damme P, Buntinx F, Vandamme A-M (2008) The epidemic history of hepatitis C among injecting drug users in Flanders. Belgium J Viral Hepat 15:399–408

    Article  Google Scholar 

  • Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Valhov D, Thomas DL (2011) Changes in blood-borne infection risk among injection drug users. J Infect Dis 203:587–594

    Article  Google Scholar 

  • Mehta SH, Cox A, Hoovere DR, Wang X, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas D (2002) Protection against persistence of Hepatitis C. Lancet 359:1478–1483

    Article  Google Scholar 

  • Meyer CD (2000) Matrix analysis and applied linear algebra. SIAM, Philadelphia

    Book  MATH  Google Scholar 

  • Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13:34–41

    Article  Google Scholar 

  • Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I (2007) High incidence of hepatitis C virus infection within a cohort of injecting drug users. J Viral Hepat 14:413–418

    Article  Google Scholar 

  • National Treatment Agency (2009) Does syringe cleaning work? http://www.harmreductionworks.org.uk/2_films/does_cleaning_syringes_work.html (accessed 2010)

  • NESI (2010) The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2008/2009. Technical report, University of the West of Scotland and Health Protection Scotland and West of Scotland Specialist Virology Centre, Paisley

  • Oden JT, Demkowicz LF (1996) Applied functional analysis: a first course for students of mechanics and engineering science (civil engineering and engineering mechanics series). CRC Press, Florida

    Google Scholar 

  • Paintsil E, He H, Peters C, Lindenbach BD, Heimer R (2010) Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 202:984–990

    Article  Google Scholar 

  • Roy E, Alary M, Morissette C, Leclerc P, Boudreau J-F, Parent R, Rochefort J, Caessens C, Group TSW (2007) High Hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J Sex Trans Dis AIDS 18:23–27

    Google Scholar 

  • Roy E, Boudreau J-F, Boivin JF (2009) Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 102:158–161

    Article  Google Scholar 

  • Scottish Executive (2008) Hepatitis C action plan for Scotland, Edinburgh. http://www.scotland.gov.uk/Resource/Doc/222750/0059978.pdf (accessed 2011)

  • Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567

    Article  Google Scholar 

  • Sutton AJ, Gray NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M (2006) Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 6:1–10

    Article  Google Scholar 

  • Taylor A, Goldberg D, Hutchinson S, Cameron S, Fox R (2001) High risk injecting behaviour among injectors from Glasgow: cross sectional community wide surveys 1990–1999. J Epidemiol Community Health 55:766–767

    Article  Google Scholar 

  • Taylor A, Goldberg D, Hutchinson S, Cameron S, Gore SM, McMenamin J, Green S, Pithie A, Fox R (2000) Prevalence of Hepatitis C virus infection among injecting drug users in Glasgow 1990–1996: are current harm reduction strategies working? J Infect 40:176–183

    Article  Google Scholar 

  • Van Beek I, Buckley R, Stewart M, MacDonald M, Kaldor J (1994) Risk factors for hepatitis C virus infection among injecting drug users in Sydney. Genitourin Med 70:321–324

    Google Scholar 

  • Vickerman P, Hickman M, Judd A (2007) Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 36:396–405

    Article  Google Scholar 

  • Vickerman P, Platt L, Hawkes S (2009) Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sex Transm Infect 85:23–30

    Article  Google Scholar 

  • World Health Organisation (2000) Hepatitis C Fact Sheet 164. World Health Organisation, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed 2009)

Download references

Acknowledgments

We would like to thank Health Protection Scotland, the Engineering and Physical Sciences Research Council and the University of Strathclyde for funding this research, as well as Health Protection Scotland and the University of West of Scotland for the provision of survey data on IDUs.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Corson.

Appendix

Appendix

1.1 A: Derivation of \(\varLambda _{jk}\) terms

Let \(\lambda _j\) denote the rate at which IDUs in experience group \(j\) share needles and syringes, \(n_j\) denote the number of IDUs in experience group \(j\) and \(s_{jk}\) denote the fraction of shared injections that an IDU in experience group \(j\) will perform while using a needle and syringe which was last used by an IDU in experience group \(k\). Then

$$\begin{aligned} \lambda _j n_j s_{jk}\varDelta t+o(\varDelta t) \end{aligned}$$

denotes the total number of shared injections in a time interval of length \(\varDelta t\) made by the entire set of IDUs in experience group \(j\) with needle and syringes that were last used by IDUs in experience group \(k\). Since there are \(m_k\) of these needles and syringes in total, the total rate at which an IDU in experience group \(j\) picks up a single one of these needles and syringes is given by

$$\begin{aligned} \varLambda _{jk}=\frac{\lambda _j s_{jk}n_j}{m_k}. \end{aligned}$$

1.2 B: Constraint on \(s_{01}\) and \(s_{10}\)

Define \(m_0\,(m_1)\) to be the number of naive (experienced) needles and syringes in circulation (as discussed in Sect. 3). Ignoring the infection status of the needles and syringes we obtain the following equations

$$\begin{aligned} \dfrac{dm_0}{dt}&= \varLambda _{01}m_1-\varLambda _{10}m_0=\lambda _0s_{01}n_0-\lambda _1s_{10}n_1,\end{aligned}$$
(53)
$$\begin{aligned} \dfrac{dm_1}{dt}&= \varLambda _{10}m_0-\varLambda _{01}m_1=\lambda _1s_{10}n_1-\lambda _0s_{01}n_0, \end{aligned}$$
(54)

where \(\varLambda _{jk}=\dfrac{\lambda _j s_{jk}n_j}{m_k}\), \(j,k=0,1\), denotes the rate at which an IDU in group \(j\) picks up a needle and syringe last used by a group \(k\) IDU and \(n_0\) and \(n_1\) are, respectively, the number of naive and experienced IDUs at time t. The above equations imply that at equilibrium

$$\begin{aligned} \varLambda _{01}m_1=\varLambda _{10}m_0, \end{aligned}$$
(55)

which implies that

$$\begin{aligned} \lambda _0s_{01}n_0=\lambda _1s_{10}n_1. \end{aligned}$$

Note that \(n_0+n_1=n\), the constant number of IDUs in the population and

$$\begin{aligned} \frac{dn_0}{dt}&= \mu n-(\mu +\eta )n_0,\\ \frac{dn_1}{dt}&= \eta n_0-\mu n_1.\nonumber \end{aligned}$$
(56)

Hence as \(t\rightarrow \infty \), \(n_0\rightarrow \mu n/(\mu +\eta )\) and \(n_1\rightarrow \eta n/(\mu +\eta )\) so this constraint becomes

$$\begin{aligned} \lambda _0s_{01}\mu =\lambda _1s_{10}\eta . \end{aligned}$$
(57)

If this condition is not satisfied then Eqs. (53) and (54) imply that one of \(m_0, m_1\) eventually becomes negative. If condition (57) is satisfied then from (56) we have

$$\begin{aligned} \dfrac{d}{dt}\left[n_0 \text{ exp}[(\mu +\eta )t]\right] =\mu n \text{ exp}[(\mu +\eta )t]\nonumber . \end{aligned}$$

Integrating over \([0, t]\) gives

$$\begin{aligned} n_0(t)\text{ exp}[(\mu +\eta )t]-n_0(0)&=\frac{\mu n}{\mu +\eta }(\text{ exp}[(\mu +\eta )t]-1), \end{aligned}$$

which implies that

$$\begin{aligned} n_0(t)=n_{0}^*+(n_0(0)-n_{0}^*)\text{ exp}[-(\mu +\eta )t], \end{aligned}$$
(58)

where \(n_{0}^*=\mu n/(\mu +\eta )\). Using Eq. (56) and the fact that \(n_1=n-n_0\) we can use a similar argument to that used above to obtain

$$\begin{aligned} n_1(t)=n_{1}^*+(n_1(0)-n_{1}^*)\text{ exp}[-(\mu +\eta )t], \end{aligned}$$
(59)

where \(n_{1}^*=\eta n/(\mu +\eta )\). Substituting (58) and (59) into Eq. (53) we find that

$$\begin{aligned} \dfrac{dm_0}{dt} =(\lambda _0s_{01}n_0(0)-\lambda _1s_{10}n_1(0))\text{ exp}[-(\mu +\eta )t]. \end{aligned}$$

Integrating over \([0, t]\) we have

$$\begin{aligned} m_0(t)=m_0(0)-\frac{1}{\mu +\eta }(\lambda _0s_{01}n_0(0)-\lambda _1s_{10}n_1(0))(\text{ exp}[-(\mu +\eta )t]-1). \end{aligned}$$

Similarly

$$\begin{aligned} m_1(t)=m_1(0)-\frac{1}{\mu +\eta }(\lambda _1s_{10}n_1(0)-\lambda _0s_{01}n_0(0))(\text{ exp}[-(\mu +\eta )t]-1). \end{aligned}$$

Hence, as \(t\rightarrow \infty \), \(m_0(t)\) monotonically tends to

$$\begin{aligned} m_0(0)+\frac{1}{\mu +\eta }(\lambda _0s_{01}n_0(0)-\lambda _1s_{10}n_1(0)). \end{aligned}$$
(60)

Similarly \(m_1(t)\) monotonically tends to

$$\begin{aligned} m_1(0)+\frac{1}{\mu +\eta }(\lambda _1s_{10}n_1(0)-\lambda _0s_{01}n_0(0)). \end{aligned}$$
(61)

So provided that both (60) and (61) are positive then \(m_0(t)\) and \(m_1(t)\) will approach strictly positive values. Furthermore, if the spread of HCV has been going on for a long period of time before the model is started we can expect that

$$\begin{aligned} n_0(0)\approx n_{0}^*(0)=\frac{\mu n}{\mu +\eta }\quad \text{ and} \quad n_1(0)\approx n_{1}^*(0)=\frac{\eta n}{\mu +\eta }. \end{aligned}$$

In this case we see from (60) and (61) that the number of needles and syringes in group will not change much from their initial values.

1.3 C: Derivation of \(\psi _0\) and \(\psi _1\)

At time \(t\), the total rate at which needles and syringes in the naive group are used is given by

$$\begin{aligned} (\varLambda _{00}+\varLambda _{10})m_0=\lambda _0s_{00}n_0+\lambda _1s_{10}n_1, \end{aligned}$$

where \(n_0\) and \(n_1\) are, respectively, the number of naive and experienced IDUs. Also the total rate at which needles and syringes in this group are used or exchanged is given by

$$\begin{aligned} (\varLambda _{00}+\varLambda _{10}+\tau _0)m_0. \end{aligned}$$

Hence the probability of choosing an unexchanged needle and syringe from the needles and syringes in the naive group is given by

$$\begin{aligned} \psi _0=\dfrac{\varLambda _{00}+\varLambda _{10}}{(\varLambda _{00}+\varLambda _{10}+\tau _0)}. \end{aligned}$$

Similarly

$$\begin{aligned} \psi _1=\dfrac{\varLambda _{11}+\varLambda _{01}}{(\varLambda _{11}+\varLambda _{01}+\tau _1)}. \end{aligned}$$

1.4 D: Derivation of K = \(\mathbf M \)(K)K

Substituting the equilibrium expressions for \(\pi _y^{0*}\), \(\pi _y^{1*}\), \(\pi _h^{0*}\) and \(\pi _h^{1*}\) given by (20), (24) and (26) into

$$\begin{aligned} K_0^*=\lambda _0s_{00}(1-\phi _0)\psi _{0}^*(\alpha _h\pi _{h}^{0*}+\alpha _y\pi _{y}^{0*})+\lambda _0s_{01}(1-\phi _0)\frac{\psi _{1}^*\pi ^{0*}}{\pi ^{1*}}(\alpha _h\pi _{h}^{1*}+\alpha _y\pi _{y}^{1*}) \end{aligned}$$

we obtain

$$\begin{aligned} K_0^*&= \left[\frac{\big (\lambda _0s_{00}(1-\phi _0)\psi _{0}^*\big (\alpha _h+\frac{\sigma (1-\delta )}{\mu +\eta }\alpha _y\big )+\lambda _0s_{01}(1-\phi _0)\psi _{1}^*\frac{\pi ^{0*}}{\pi ^{1*}}\frac{\eta \sigma (1-\delta )\alpha _y}{\mu (\mu +\eta )}\big )\frac{1}{\mu +\sigma +\eta }}{1+\frac{K_0^*}{\mu +\sigma +\eta }\big (\frac{\mu +\eta }{\mu }+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )}\right.\\&\!\!\left.+\frac{\lambda _0s_{01}(1-\phi _0)\psi _{1}^*\frac{\pi ^{0*}}{\pi ^{1*}}\big (\alpha _h+\frac{\sigma (1-\delta )}{\mu }\alpha _y\big )\frac{\eta }{\mu +\sigma }\frac{1}{\mu +\sigma +\eta }}{\bigg [1+\frac{K_0^*}{\mu +\sigma +\eta }\big (\frac{\mu +\eta }{\mu }+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]\bigg [1+\frac{K_1^*}{\mu +\sigma }\frac{\mu +\eta }{\eta }\big (1+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]}\right]K_0^*\\&\!\!+\left[\frac{\lambda _0s_{01}(1-\phi _0)\psi _{1}^*\frac{\pi ^{0*}}{\pi ^{1*}}\big (\alpha _h+\frac{\sigma (1-\delta )}{\mu }\alpha _y\big )\frac{1}{\mu +\sigma }\big (1+\frac{K_0^*}{\mu +\sigma +\eta }\frac{\mu +\eta }{\eta }\big )}{\bigg [1+\frac{K_0^*}{\mu +\sigma +\eta }\big (\frac{\mu +\eta }{\mu }+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]\bigg [1+\frac{K_1^*}{\mu +\sigma }\frac{\mu +\eta }{\eta }\big (1+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]}\right]K_1^*\\&= M_{00}({\varvec{K}}^*)K_0^*+M_{01}({\varvec{K}}^*)K_1^*. \end{aligned}$$

Here \(M_{00}({\varvec{K}}^*)\) is the first term in the large square brackets multiplying \(K_0^*, M_{01}({\varvec{K}}^*)\) is the second term in the large square brackets multiplying \(K_1^*\), and \({\varvec{K}}^*=({\varvec{K}}_1^*, {\varvec{K}}_2^*)\). Similarly

$$\begin{aligned} K_1^*&= \left[\frac{\big (\lambda _1s_{10}(1-\phi _1)\psi _{0}^*\frac{\pi ^{1*}}{\pi ^{0*}}\big (\alpha _h+\frac{\sigma (1-\delta )}{\mu +\eta }\alpha _y\big )+\lambda _1s_{11}(1-\phi _1)\psi _{1}^*\frac{\eta \sigma (1-\delta )\alpha _y}{\mu (\mu +\eta )}\big )\frac{1}{\mu +\sigma +\eta }}{1+\frac{K_0^*}{\mu +\sigma +\eta }\big (\frac{\mu +\eta }{\mu }+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )}\right.\\&\left.+\frac{\lambda _1s_{11}(1-\phi _1)\psi _{1}^*\big (\alpha _h+\frac{\sigma (1-\delta )}{\mu }\alpha _y\big )\frac{\eta }{\mu +\sigma }\frac{1}{\mu +\sigma +\eta }}{\bigg [1+\frac{K_0^*}{\mu +\sigma +\eta }\big (\frac{\mu +\eta }{\mu }+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]\bigg [1+\frac{K_1^*}{\mu +\sigma }\frac{\mu +\eta }{\eta }\big (1+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]}\right]K_0^*\\&+\left[\frac{\lambda _1s_{11}(1-\phi _1)\psi _{1}^*\big (\alpha _h+\frac{\sigma (1-\delta )}{\mu }\alpha _y\big )\frac{1}{\mu +\sigma }\big (1+\frac{K_0^*}{\mu +\sigma +\eta }\frac{\mu +\eta }{\eta }\big )}{\bigg [1+\frac{K_0^*}{\mu +\sigma +\eta }\big (\frac{\mu +\eta }{\mu }+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]\bigg [1+\frac{K_1^*}{\mu +\sigma }\frac{\mu +\eta }{\eta }\big (1+\frac{\sigma (1-\delta )}{\mu }+\frac{\sigma \alpha \delta }{\mu }\big )\bigg ]}\right]K_1^*\\&= M_{10}({\varvec{K}}^*)K_0^*+M_{11}({\varvec{K}}^*)K_1^*. \end{aligned}$$

Similarly to the above \(M_{10} ({\varvec{K}}^*)\) is the first term in the large square brackets multiplying \(K_0^*\) and \(M_{11}({\varvec{K}}^*)\) is the second term in the large square brackets multiplying \(K_1^*\).

Hence, it is possible to write this system in the form

$$\begin{aligned} {\varvec{K}}^*= \begin{bmatrix} K_0^*\\ K_1^* \end{bmatrix} = \begin{bmatrix} M_{00}({\varvec{K}}^*)&\quad M_{01}({\varvec{K}}^*)\\ M_{10}({\varvec{K}}^*)&\quad M_{11}({\varvec{K}}^*) \end{bmatrix} \begin{bmatrix} K_0^*\\ K_1^* \end{bmatrix} = \mathbf M ({\varvec{K}}^*){\varvec{K}}^*. \end{aligned}$$

If we examine the \(M_{00}({\varvec{K}}^*)\), \(M_{01}({\varvec{K}}^*), M_{10}({\varvec{K}}^*)\) and \(M_{11}({\varvec{K}}^*)\) terms more closely we can see that each term is greater than or equal to zero and strictly decreasing in \(K_0^*\) and \(K_1^*\). In addition, we see that

$$\begin{aligned} \mathbf M ({\varvec{0}})^{T} = \begin{bmatrix} M_{00}({\varvec{0}})&\quad M_{10}({\varvec{0}})\\ M_{01}({\varvec{0}})&\quad M_{11}({\varvec{0}}) \end{bmatrix}, \end{aligned}$$

where

$$\begin{aligned} M_{00}({\varvec{0}})&= \dfrac{\lambda _0s_{00}(1-\phi _0)\psi _{0}^*}{(\mu +\sigma +\eta )}\bigg [\alpha _h+\dfrac{\sigma (1-\delta )\alpha _y}{(\mu +\eta )}\bigg ] +\lambda _0s_{01}(1-\phi _0)\psi _{1}^*\dfrac{\pi ^{0*}}{\pi ^{1*}}\\&\times \frac{\eta }{(\mu +\sigma +\eta )}\bigg [\frac{\alpha _h}{\mu +\sigma }+\frac{\sigma (1-\delta )\alpha _y}{\mu (\mu +\sigma )} +\frac{\sigma (1-\delta )\alpha _y}{\mu (\mu +\eta )}\bigg ],\\&= \kappa _{00},\\ M_{01}({\varvec{0}})&= \dfrac{\lambda _0s_{01}(1-\phi _0)\psi _{1}^*}{(\mu +\sigma )}\dfrac{\pi ^{0*}}{\pi ^{1*}}\bigg [\alpha _h+\dfrac{\sigma (1-\delta )\alpha _y}{\mu }\bigg ],\\&= \kappa _{10},\\ M_{10}({\varvec{0}})&= \dfrac{\lambda _1s_{10}(1-\phi _1)\psi _{0}^*}{(\mu +\sigma +\eta )}\dfrac{\pi ^{1*}}{\pi ^{0*}}\bigg [\alpha _h+\dfrac{\sigma (1-\delta )\alpha _y}{\mu +\eta }\bigg ]\\&+\,\lambda _1s_{11}(1-\phi _1)\psi _{1}^*\dfrac{\eta }{(\mu +\sigma +\eta )} \bigg [\frac{\alpha _h}{\mu +\sigma }+\frac{\sigma (1-\delta )\alpha _y}{\mu (\mu +\eta )} +\frac{\sigma (1-\delta )\alpha _y}{\mu (\mu +\sigma )}\bigg ],\\&= \kappa _{01}, \end{aligned}$$

and

$$\begin{aligned} M_{11}({\varvec{0}})&= \dfrac{\lambda _1s_{11}(1-\phi _1)\psi _{1}^*}{(\mu +\sigma )}\bigg [\alpha _h+\dfrac{\sigma (1-\delta )\alpha _y}{\mu }\bigg ],\\&= \kappa _{11}. \end{aligned}$$

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corson, S., Greenhalgh, D. & Hutchinson, S.J. A time since onset of injection model for hepatitis C spread amongst injecting drug users. J. Math. Biol. 66, 935–978 (2013). https://doi.org/10.1007/s00285-012-0577-y

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00285-012-0577-y

Keywords

Mathematics Subject Classification (2000)

Navigation